CPRX

21.15

1.12% -0.24

Pre-mercato: 21.15

Catalyst Pharmaceuticals Inc (CPRX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché CPRX Giù? Forum Previsione

Precedente Chiudi:

$21.39

Aprire:

$21.52

Volume 24 ore:

933.65K

Relative Volume:

1.02

Capitalizzazione di mercato:

$2.55B

Reddito:

$434.48M

Utile/perdita netta:

$68.15M

Rapporto P/E:

20.94

EPS:

1.01

Flusso di cassa netto:

$114.96M

1 W Prestazione:

-7.24%

1M Prestazione:

-0.42%

6M Prestazione:

+25.00%

1 anno Prestazione:

+54.27%

Intervallo 1D:

$21.05

$21.63

Intervallo di 1 settimana:

$20.44

$22.78

Portata 52W:

$13.00

$24.27

Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile

Nome

Catalyst Pharmaceuticals Inc

Settore

Healthcare (1193)

Industria

Biotechnology (683)

Telefono

(305) 529-2522

Indirizzo

355 ALHAMBRA CIRCLE, CORAL GABLES

Dipendente

167

Cinguettio

@CatalystForRare

Prossima data di guadagno

2024-11-06

Ultimi documenti SEC

CPRX's Discussions on Twitter

Confronta CPRX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CPRX	21.15	2.55B	434.48M	68.15M	114.96M	1.01
VRTX	451.23	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.82	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.14	24.49B	3.30B	-501.07M	1.03B	11.54

Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-03-14	Iniziato	Citigroup	Buy
2024-03-07	Iniziato	BofA Securities	Buy
2023-12-21	Iniziato	Oppenheimer	Outperform
2022-08-24	Downgrade	ROTH Capital	Buy → Neutral
2018-09-21	Iniziato	Cantor Fitzgerald	Overweight
2018-09-07	Ripresa	Piper Jaffray	Overweight
2016-10-05	Aggiornamento	Piper Jaffray	Neutral → Overweight
2016-04-26	Downgrade	Piper Jaffray	Overweight → Neutral
2014-09-30	Reiterato	ROTH Capital	Buy
2014-09-16	Reiterato	ROTH Capital	Buy
2014-09-15	Reiterato	H.C. Wainwright	Buy
2013-10-21	Reiterato	Aegis Capital	Buy
2013-09-24	Iniziato	Maxim Group	Buy
2013-09-06	Reiterato	Aegis Capital	Buy
2013-04-18	Iniziato	Aegis Capital	Buy
2012-08-27	Aggiornamento	Rodman & Renshaw	Mkt Perform → Mkt Outperform
2009-10-01	Aggiornamento	Merriman	Sell → Neutral
2009-05-29	Downgrade	Hapoalim	Neutral → Underperform
2009-05-29	Downgrade	Merriman Curhan Ford	Buy → Sell
2008-12-15	Iniziato	Merriman Curhan Ford	Buy
2007-11-28	Iniziato	Rodman & Renshaw	Mkt Outperform
2007-01-31	Iniziato	Stifel Nicolaus	Buy
2007-01-05	Iniziato	First Albany	Buy

Mostra tutto

Catalyst Pharmaceuticals Inc Borsa (CPRX) Ultime notizie

Nov 20, 2024

Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Nov 20, 2024

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire

Nov 20, 2024

Nov 19, 2024

Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Nov 19, 2024

Catalyst Pharmaceuticals CEO to Present at Major Healthcare Conferences | CPRX Stock News - StockTitan

Nov 19, 2024

GSA Capital Partners LLP Makes New $625,000 Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Nov 19, 2024

Nov 18, 2024

Catalyst Pharmaceuticals (NASDAQ:CPRX) Coverage Initiated at Stephens - MarketBeat

Nov 18, 2024

Principal Financial Group Inc. Has $11.45 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Nov 18, 2024

Stephens & Co. Initiates Coverage of Catalyst Pharmaceuticals (CPRX) with Overweight Recommendation - MSN

Nov 18, 2024

Nov 15, 2024

Catalyst Pharmaceuticals chairman sells shares worth $3.1 million - Investing.com

Nov 15, 2024

Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch

Nov 15, 2024

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock - Yahoo Finance

Nov 15, 2024

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Royce & Associates LP - MarketBeat

Nov 15, 2024

Nov 14, 2024

Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Nov 14, 2024

Catalyst Pharmaceuticals Board Member Trades $11.51M In Company Stock - Benzinga

Nov 14, 2024

Nov 13, 2024

Catalyst Pharmaceuticals chairman sells $11.5 million in stock - Investing.com

Nov 13, 2024

Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work - The Manila Times

Nov 13, 2024

Catalyst Pharmaceuticals Named Among BioSpace's Top 50 Best Places to Work 2025 | CPRX Stock News - StockTitan

Nov 13, 2024

We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve - Simply Wall St

Nov 13, 2024

Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting Point - Yahoo Finance

Nov 13, 2024

Los Angeles Capital Management LLC Buys 123,020 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Nov 13, 2024

Nov 12, 2024

Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Nov 12, 2024

Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $30.50 - MarketBeat

Nov 12, 2024

CWA Asset Management Group LLC Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Nov 12, 2024

Nov 11, 2024

Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch

Nov 11, 2024

Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target Raised to $36.00 at Truist Financial - MarketBeat

Nov 11, 2024

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Meritage Portfolio Management - MarketBeat

Nov 11, 2024

Nov 10, 2024